Table 1.
Demographical and clinical manifestations of patients with acute respiratory failure revealing anti-synthetase syndrome or dermato-pulmonary syndrome associated with anti-MDA-5 antibodies
| Missing data | All patients N = 47 |
aMDA-5 ARF N = 19 |
AS ARF N = 28 |
p | |
|---|---|---|---|---|---|
| Age, years median [IQR] | 0 | 60 [52–69] | 60 [51–67] | 63 [54–73] | 0.51 |
| Male, n (%) | 0 | 23 (49) | 8 (42) | 15 (54) | 0.64 |
| SOFA score median [IQR] | 0 | 5 [3–8] | 4 [2–8] | 5 [3–8] | 0.77 |
| SAPSII median [IQR] | 0 | 35 [27–53] | 34 [27–53] | 38 [27–50] | 0.94 |
| Comorbidities, n (%) | |||||
| Chronic respiratory failure | 0 | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| Congestive heart failure | 0 | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Cirrhosis | 0 | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| Chronic kidney failure | 0 | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Active solid cancer or malignant hemopathy | 0 | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| HIV | 0 | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Diabetes mellitus | 0 | 5 (11) | 1 (5) | 4 (14) | 0.64 |
| Obesity (body mass index ≥ 30 kg/m2) | 0 | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| No comorbidities | 0 | 40 (85) | 18 (95) | 22 (79) | 0.60 |
| Active or former tobacco use, n (%) | 0 | 20 (43) | 7 (37) | 13 (46) | 0.73 |
| Respiratory manifestations, n (%) | |||||
| Delay first respiratory sign—ICU admission, days | 2 | 21 [10–41] | 21 [11–43] | 21 [10–41] | 0.73 |
| Dry cough | 0 | 23 (49) | 8 (42) | 15 (54) | 0.64 |
| Chest pain | 0 | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Hemoptysis | 0 | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| Bilateral crackles | 5 | 34 (81) | 13 (77) | 21 (84) | 0.69 |
| Fever (> 38 °C) | 0 | 27 (57) | 9 (47) | 18 (64) | 0.40 |
| Extra-respiratory manifestations, n (%) | |||||
| Myalgia | 0 | 11 (23) | 2 (11) | 9 (32) | 0.16 |
| Muscles weakness | 0 | 6 (13) | 1 (5) | 5 (18) | 0.38 |
| Arthralgia/arthritis | 0 | 14 (30) | 6 (32) | 8 (29) | 1.00 |
| Cutaneous manifestations | 0 | 20 (43) | 13 (68) | 7 (25) | 0.008 |
| Mechanic’s hand | 0 | 8 (17) | 3 (15) | 5 (19) | 1.00 |
| Raynaud’s phenomenon | 0 | 3 (6) | 1 (5) | 2 (7) | 1.00 |
| Facial erythema | 0 | 12 (26) | 9 (47) | 3 (11) | 0.007 |
| Gottron’s papules | 0 | 5 (11) | 5 (26) | 0 (0) | 0.008 |
| Ulcerations | 0 | 3 (6) | 3 (16) | 0 (0) | 0.06 |
| Trunk rash | 0 | 7 (15) | 5 (26) | 2 (7) | 0.10 |
| No extra-respiratory manifestations | 0 | 17 (36) | 6 (31) | 11 (39) | 0.81 |
aMDA-5 anti-MDA-5 antibodies, AS anti-synthetase, ARF acute respiratory failure, HIV human immunodeficiency virus, ICU intensive care unit, IQR inter-quartile range, SAPS2 simplified acute physiology score, SOFA sepsis-related organ failure assessment